A recent study identified orosomucoid 2 (ORM2) as a key regulatory protein in de novo lipogenesis in non-alcoholic steatohepatitis and showed preclinical data on beneficial pharmacological targeting.6 This evidence concerns the gene ORM2 and metabolic dysfunction-associated steatohepatitis.